INGN Stock Analysis: Buy, Sell, or Hold?
INGN - Inogen Inc
$6.54
0.00 (0.00%)
▲
5d:
-1.95%
30d:
-0.76%
90d:
+3.32%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Get Alerted When INGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INGN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: INGN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: INGN is currently trading at $6.54, which is considered fair relative to its 30-day fair value range of $6.33 to $6.71. From a valuation perspective, the stock is trading at a discount (Forward PE: -25.1) compared to its historical average (120.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INGN is in a uptrend. The price is approaching resistance at $6.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INGN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.67 (+93.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INGN is in a uptrend. The price is approaching resistance at $6.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INGN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.67 (+93.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$6.33 -
$6.71
Company Quality Score
56/100
(HOLD)
Options IV Signal
53th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
84.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 53th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 93.7% below Wall St target ($12.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$6.33 -
$6.71
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.08
(16.5%)
Support & Resistance Levels
Support Level
$5.88
Resistance Level
$6.72
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.15
Wall Street Target
$12.67
(+93.7%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
87.3%
Profit Margin
-7.1%
PE vs Historical
-25.2 vs 120.2
CHEAP
Share & Embed Analysis
Last updated: July 13, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$74 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 67 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 57 HOLD |
